February 14, 2023
FDA: Class I recall of Skippack Medical Lab COVID-19 tests
Editor's Note
The Food and Drug Administration (FDA) on February 8 identified the recall by Universal Meditech Inc of its Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold) as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
Distribution dates were January 2022.
Free Daily News
- HFMA warns affordability crisis is driving up provider bad debt
- Report warns sterile processing staffing crisis threatens surgical safety
- Ascension swings to profit as outpatient push, cost cuts take hold
- High BMI alone did not raise early complication risk after outpatient TJA
- AAAHC report spotlights top accreditation deficiencies, strategies for safer ambulatory care
- ACS conference charts bold future for surgical quality with data, teamwork, frontline innovation
- Surgical leaders urged to weigh risks, rewards of innovation with a critical eye
- Health systems report dramatic nurse retention gains through residency, development programs
- Surgical innovation redefines what is possible for advanced colorectal cancer
- CMS proposal to end inpatient only list draws strong industry response
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement